Intelligence Profile
Research Papers
Research Papers and Clinical Trials on Delgocitinib
Delgocitinib for Atopic Dermatitis:
A Phase IIb trial published in The British Journal of Dermatology examined the effects of Delgocitinib cream in adults with mild to severe atopic dermatitis. This 8-week randomized study demonstrated a dose-dependent response, indicating its efficacy across varying dosages (PMID: 42483929).
Treatment of Vulvar Lichen Sclerosus:
A case report in JAAD Case Reports highlighted Delgocitinib's potential in treating refractory vulvar lichen sclerosus, although specific details about the study size or outcomes weren’t detailed in the summary provided (PMID: 42436909).
Chronic Hand Eczema:
Multiple studies have assessed Delgocitinib for hand eczema. An article in Expert Opinion on Pharmacotherapy evaluated its use in moderate to severe cases, while a letter in Dermatitis reported improvements in quality of life for chronic hand eczema patients using this treatment (PMIDs: 42429252, 42318861).
A Phase 2b trial (NCT03683719) aimed to determine the optimal dosage over a 16-week period, evaluating doses ranging from 1 mg/g to 20 mg/g. This trial was completed, showing promising results across different concentrations.
A related real-world evidence study (NCT07603193) is enrolling by invitation, potentially adding further insights into the effectiveness and safety of Delgocitinib for hand eczema.
Miscellaneous Applications:
A systematic review in Pediatric Dermatology included topical Janus kinase inhibitors like Delgocitinib for pediatric atopic dermatitis, but specific findings were not detailed in the available evidence (PMID: 42289185).
Additionally, a Phase 2 clinical trial (NCT05332366) investigated Delgocitinib cream for frontal fibrosing alopecia, examining molecular signature and efficacy.
Safety and Efficacy:
A Phase 1 trial (NCT04807751) explored the safety of Delgocitinib when exposed to UV-light, assessing the potential for allergic skin reactions. This study's results may support understanding of its safety profile under diverse conditions.
Conclusion:
Delgocitinib shows promise across various dermatological conditions, with ongoing studies to further clarify its efficacy and safety. However, further real-world data and larger-scale trials could enhance understanding of its broader applications.
Disclaimer: This overview is informational and not a substitute for professional medical advice. Always consult a healthcare provider for personal health concerns.